Evotec SE has extended and expanded its partnership with Bristol Myers Squibb in targeted protein degradation, originally signed in 2018. The initial collaboration has proven to be highly productive in generating a promising pipeline of molecular glue degraders.
Molecular glue degraders are small, drug-like compounds that induce interactions between an E3 ubiquitin ligase and a molecular target. This induced interaction results in ubiquitination and subsequent degradation of the recruited protein leading to long-lasting therapeutic effects. Bristol Myers Squibb is a leader in this field based on its unique library of cereblon E3 ligase modulators (CELMoD®). Under the terms of the agreement, both parties will leverage all of Evotec’s proprietary EVOpanOmics and EVOpanHunter platforms as well as AI/ML-based drug discovery and development platforms.
Learn more about the partnership here: www.evotec.com/en/investor-re...
--
Learn more about our Data-Driven R&D Autobahn to Cures:
hubs.ly/Q0145qyP0
Join our community at the Science Pool!
hubs.ly/Q0145r650
Interested in our services? Contact us:
hubs.ly/Q0145rf70
Linkedin: hubs.ly/Q0145rpl0
Twitter: @Evotec
#researchneverstops